Research Analysts Offer Predictions for ELDN FY2026 Earnings

Eledon Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Noble Financial raised its FY2026 EPS forecast to a loss of $0.58 per share from a projected loss of $0.74; the consensus estimate remains a loss of $0.74. It also forecasts a Q4 2026 loss of $0.20 per share.
  • Eledon reported a quarterly loss of $0.18 per share, slightly better than analysts’ expected loss of $0.19.
  • Analyst opinions are split, with one Buy and one Sell rating; MarketBeat reports an average Hold rating and a $12 average price target.
  • MarketBeat previews the top five stocks to own by December 1st.

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Equities research analysts at Noble Financial boosted their FY2026 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a research report issued to clients and investors on Monday, November 16th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings per share of ($0.58) for the year, up from their previous forecast of ($0.74). The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.74) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals' Q4 2026 earnings at ($0.20) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01.

A number of other equities analysts have also issued reports on ELDN. Wall Street Zen raised Eledon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday. Rodman & Renshaw began coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, July 21st. They set a "buy" rating and a $12.00 price target for the company. Finally, Weiss Ratings upgraded shares of Eledon Pharmaceuticals from a "sell (d-)" rating to a "sell (d)" rating in a research note on Monday, November 9th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $12.00.

View Our Latest Stock Report on ELDN

Eledon Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ ELDN opened at $1.98 on Wednesday. Eledon Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $4.49. The business has a 50 day moving average price of $2.52 and a two-hundred day moving average price of $3.11. The firm has a market cap of $167.23 million, a PE ratio of -2.71 and a beta of 0.95.

Hedge Funds Weigh In On Eledon Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ELDN. BlackRock Inc. acquired a new position in shares of Eledon Pharmaceuticals in the 2nd quarter worth approximately $20,188,000. AWM Investment Company Inc. bought a new stake in shares of Eledon Pharmaceuticals in the 2nd quarter valued at approximately $4,334,000. Bank of America Corp DE bought a new stake in shares of Eledon Pharmaceuticals in the 2nd quarter valued at approximately $3,479,000. ADAR1 Capital Management LLC acquired a new stake in shares of Eledon Pharmaceuticals during the 2nd quarter valued at approximately $2,552,000. Finally, Triumph Capital Management acquired a new stake in shares of Eledon Pharmaceuticals during the 2nd quarter valued at approximately $1,196,000. 56.77% of the stock is currently owned by institutional investors and hedge funds.

About Eledon Pharmaceuticals

(Get Free Report)

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company's research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS). Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS.

Featured Stories

Earnings History and Estimates for Eledon Pharmaceuticals (NASDAQ:ELDN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eledon Pharmaceuticals Right Now?

Before you consider Eledon Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.

While Eledon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines